LENZ Therapeutics, Inc. (LENZ)
3.20
-0.30
(-8.57%)
USD |
NASDAQ |
Nov 18, 16:00
3.21
+0.01
(+0.31%)
After-Hours: 20:00
LENZ Therapeutics Enterprise Value : -86.87M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | -86.87M |
| November 16, 2026 | -76.82M |
| November 13, 2026 | -67.08M |
| November 12, 2026 | -68.33M |
| November 11, 2026 | -67.70M |
| November 10, 2026 | -68.02M |
| November 09, 2026 | -62.05M |
| November 06, 2026 | -86.87M |
| November 05, 2026 | -102.27M |
| November 04, 2026 | -88.13M |
| November 03, 2026 | -86.87M |
| November 02, 2026 | -101.01M |
| October 30, 2026 | -101.01M |
| October 29, 2026 | -87.19M |
| October 28, 2026 | -95.98M |
| October 27, 2026 | -97.87M |
| October 26, 2026 | -98.03M |
| October 23, 2026 | -97.55M |
| October 22, 2026 | -94.73M |
| October 21, 2026 | -95.67M |
| October 20, 2026 | -96.61M |
| October 19, 2026 | -93.16M |
| October 16, 2026 | -94.10M |
| October 15, 2026 | -84.67M |
| October 14, 2026 | -89.07M |
| Date | Value |
|---|---|
| October 13, 2026 | -90.01M |
| October 12, 2026 | -83.41M |
| October 09, 2026 | -82.31M |
| October 08, 2026 | -85.93M |
| October 07, 2026 | -83.10M |
| October 06, 2026 | -77.76M |
| October 05, 2026 | -84.04M |
| October 02, 2026 | -84.36M |
| October 01, 2026 | -77.76M |
| September 30, 2026 | -76.19M |
| September 29, 2026 | -98.16M |
| September 28, 2026 | -95.02M |
| September 25, 2026 | -96.44M |
| September 24, 2026 | -102.56M |
| September 23, 2026 | -101.31M |
| September 22, 2026 | -89.68M |
| September 21, 2026 | -91.25M |
| September 18, 2026 | -91.57M |
| September 17, 2026 | -89.68M |
| September 16, 2026 | -89.37M |
| September 15, 2026 | -86.54M |
| September 14, 2026 | -79.00M |
| September 11, 2026 | -77.43M |
| September 10, 2026 | -71.15M |
| September 09, 2026 | -65.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| EyePoint, Inc. | -69.60M |
| Ligand Pharmaceuticals, Inc. | 6.579B |
| Bristol Myers Squibb Co. | 157.63B |
| Context Therapeutics, Inc. | -18.49M |
| Neumora Therapeutics, Inc. | 31.03M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.97M |
| Revenue (Quarterly) | 3.384M |
| Total Expenses (Quarterly) | 34.35M |
| EPS Diluted (Quarterly) | -0.9856 |
| Gross Profit Margin (Quarterly) | 86.58% |
| Profit Margin (Quarterly) | -915.2% |
| Earnings Yield | -140.0% |
| Normalized Earnings Yield | -140.05 |